(redirected from Copegus)
Also found in: Thesaurus, Medical.


A synthetic antiviral ribonucleoside that inhibits DNA and RNA replication, used to treat lung infections caused by respiratory syncytial virus in infants and young children and in combination with an interferon to treat hepatitis C infection.

[Probably rib(onucleic) a(cid) + vir(us) + -in.]


(Medicine) an antiviral drug used against many viruses such as influenza, and, in combination with other drugs, hepatitis C


(ˈraɪ bəˌvaɪ rɪn)

a synthetic compound, C8H12N4O5, active against several DNA and RNA viruses.
[1965–70; probably by shortening and alter. of ribofuranosyl, a component of its chemical name (see ribose, furan, -ose2, -yl) + vir (us) + -in1]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.ribavirin - an inhaled antiviral agent (trade name Virazole) that may be used to treat serious virus infections
antiviral, antiviral agent, antiviral drug - any drug that destroys viruses


n ribavirina
References in periodicals archive ?
COPEGUS (ribavirin) tablets: highlights of prescribing information.
Sovaldi is usually given with ribavirin (Xolox, Copegus, Rebetol, Ribasphere, Riba Tab) with or without peginter feronalfa (Pegasys, PegIntron).
As an option for the treatment of genotype 1 chronic hepatitis C in adults with compensated liver disease, NIC to recommending Incivo in combination with Roche's Pegasus and Copegus.
In the study, approximately 200 chronically infected genotype 1 hepatitis C patients are expected to receive ANA598 200 mg twice a day (bid) in combination with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin, USP) (a current standard of care, or SOC) with a loading dose of 800 mg bid on day one.
In the Phase II study, naive genotype 1 patients will receive ANA598 or placebo in combination with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin, USP) (a current standard of care, or SOC) for 12 weeks at dose levels of 200 mg or 400 mg twice daily (bid), each with a loading dose of 800 mg bid on day one.
The Prove 3 trial, presented at the European Association for the Study of the Liver in Copenhagen, found adding the drug to Roche Holding AG's Pegasys and Copegus improved response to therapy.
On January 12, 2009, InterMune announced top-line results from a 14-day study of ITMN-191 in combination with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin).
Roche has announced that the European Commission has approved a shortened, 16-week course of treatment with Pegasys (peginterferon alfa-2a (40 KD)) plus Copegus (ribavirin) for certain hepatitis C patients.
In February 2005, the FDA approves the combination of Pegasys (peg-Interteron) and Copegus (ribavirin) for the treatment of HCV in HIV-positive patients.
Recommended Dosage: Pegasys 180 mcg subcutaneously once a week alone or with Copegus 800 mg per day orally, in two divided doses, for 48 weeks, regardless of HCV genotype.
Pegasus and Copegus indications expanded to include treatment of hepatitis C and HIV coinfection, 2005-03-02
The most important boost to morale, though, came from the launch of two products: the hepatitis C drugs Pegasys and Copegus, and the AIDS drug Fuzeon.